

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

03 Jul 2026

### Cytopathologic and Colposcopic findings evaluation of supplementation therapy on cervix precancerous lesion

#### Protocol summary

##### Summary

Study propose: the effect of multivitamin on cervix precancerous lesion. Study design: RCT (double blind). Study Population: 120 patients with abnormal pop smear ( ASCUS, ASC-H,LSIL) and related clinical symptoms and signs at Fatemiyeh hospital. Inclusion criteria: Cervical intraepithelial Neoplasia (CIN1); Atypical cell with HPV positive. Exclusion criteria: CIN2 or more in primary pathology report after biopsy. Intervention: mineral and multivitamin and 30 mg per day Q10 during 3 mounts and plasebo for control group. Outcome: disappear of lesion in CIN1 level.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2014102719694N1**  
Registration date: **2015-05-10, 1394/02/20**  
Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2015-05-10, 1394/02/20

##### Registrant information

##### Name

Azar Pirdehghan

##### Name of organization / entity

Hamadan university of medical sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 81 3838 0572

##### Email address

a.pirdehghan@umsha.ac.ir

#### Recruitment status

##### Recruitment complete

##### Funding source

Vice chancellor for research, Hamadan University of Medical Sciences

##### Expected recruitment start date

2015-02-17, 1393/11/28

##### Expected recruitment end date

2016-02-19, 1394/11/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Cytopathologic and Colposcopic findings evaluation of supplementation therapy on cervix precancerous lesion

##### Public title

The effect of multivitamine on precancerous leision of cervix

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria: Cervical intraepithelial Neoplasia (CIN1); Atypical cell with HPV positive. Exclusion criteria: CIN2 or more in primary pathology report after biopsy.

##### Age

No age limit

##### Gender

Female

##### Phase

2

##### Groups that have been masked

No information

##### Sample size

Target sample size: **120**

##### Randomization (investigator's opinion)

Randomized

**Randomization description**  
**Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Hamadan university of medical sciences ethical committee

**Street address**

Ethical committee, Medical school, Hamadan University of medical sciences, Hamadan, Iran.

**City**

Hamadan

**Postal code****Approval date**

2015-03-02, 1393/12/11

**Ethics committee reference number**

6367/9/35/16پ

**Health conditions studied****1****Description of health condition studied**

Cervix cancer

**ICD-10 code**

C53

**ICD-10 code description**

Malignant neoplasm of cervix uteri

**Primary outcomes****1****Description**

Cure of Cin1 lesion

**Timepoint**

Pre intervention, 6 months after trial

**Method of measurement**

Pathology report

**Secondary outcomes**

empty

**Intervention groups****1****Description**

Mineral and multivitamin and 30 mg per day Q10 during 3 mounts in intervention group

**Category**

Treatment - Drugs

**2****Description**

control group: plasebo

**Category**

Placebo

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Fatemiyeh Hospital

**Full name of responsible person**

Mehrangiz Zamani

**Street address**

Fatemiyeh Hospital, Kermanshah street, Hamadan, Iran.

**City**

Hamadan

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Vice chancellor for research, Hamadan university of medical sciences

**Full name of responsible person**

Saeed Bashirian

**Street address**

Vice chancellor for research, Hamadan University of medical sciences, Hamadan, Iran.

**City**

Hamadan

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice chancellor for research, Hamadan university of medical sciences

**Proportion provided by this source**

100

**Public or private sector**

empty

**Domestic or foreign origin**

empty

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

*empty*

**Person responsible for general inquiries****Contact****Name of organization / entity**

Hamadan university of medical sciences

**Full name of responsible person**

Danial Farhadi

**Position**

Medical student

**Other areas of specialty/work****Street address**

Community medicine department, Medical school,  
Hamadan University of medical sciences, Hamadan,  
Iran.

**City**

Hamadan

**Postal code****Phone**

+98 81 3838 0572

**Fax****Email**

Danifarhadi20@Gmail.com

**Web page address****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Hamadan university of medical sciences

**Full name of responsible person**

Azar Pirdehghan

**Position**

Community medicine assistant proffessor

**Other areas of specialty/work****Street address**

Community medicine department, Medical school,  
Hamadan University of medical sciences, Hamadan,  
Iran.

**City**

Hamadan

**Postal code****Phone**

+98 81 3838 0572

**Fax****Email**

a.pirdehghan@umsha.ac.ir

**Web page address****Person responsible for updating data****Contact****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*